Aligos Therapeutics, Inc. (ALGS) › Operating Cash FlowAligos Therapeutics, Inc. (ALGS) — Operating Cash FlowAnnual figures by fiscal year, from SEC filings.2019: -$46.77M2020: -$74.26M2021: -$115.66M2022: -$79.39M2023: -$79.00M2024: -$80.74M2025: -$82.50M-$82.50M2019Operating Cash Flow (USD)2025Fiscal YearOperating Cash FlowChange YoY2025-$82.50M-2.2%2024-$80.74M-2.2%2023-$79.00M+0.5%2022-$79.39M+31.4%2021-$115.66M-55.7%2020-$74.26M-58.8%2019-$46.77M—Other metrics: RevenueCost of RevenueGross ProfitOperating IncomeNet IncomeEPS (Diluted)Total AssetsTotal LiabilitiesShareholders' EquityCash & EquivalentsCapital ExpendituresShares OutstandingDividends Per Share